Dr. James Z. Liu, MD, PhD, is a physician, biomedical researcher, and healthcare innovator with extensive experience in clinical research and medical technology development. He is the Co-Founder and CEO of Tesla BioHealing and DrNaturalHealing, Inc., and President of First Institute of All Medicines. Dr. Liu previously held leadership roles at AstraZeneca, Johnson & Johnson, and Abbott Laboratories, leading international clinical research and FDA-related projects. He has authored 89 U.S. and international patents and received multiple awards for his contributions to medical and nutritional research. Dr. Liu earned his MD from Shandong University School of Medicine and PhD in Human Nutrition from Pennsylvania State University.

" How Biophoton Platform Technology Contributes to Overcoming the Epidemiology of Chronic Diseases"                                                                                                                                                                             Background: Chronic diseases—including neurodegenerative disorders, metabolic syndromes, and persistent inflammatory conditions—represent the leading global health burden, accounting for most of the morbidity and mortality worldwide. Despite advances in pharmacological and behavioral interventions, current strategies largely focus on symptom management rather than addressing underlying systemic dysfunctions such as impaired cellular energy metabolism, oxidative stress, and chronic inflammation. There is an urgent need for innovative, non-invasive approaches that can complement existing public health strategies and target fundamental biological processes contributing to chronic disease epidemiology.Objective: This study explores the potential contribution of biophoton platform technology—an emerging biophysical modality utilizing non-thermal photon emissions—to the prevention, management, and epidemiological reduction of chronic diseases.Methods: A translational research framework was employed, integrating observational clinical data, pilot studies, and mechanistic insights from photobiomodulation science. The platform’s effects were evaluated across multiple domains, including neurological disorders, chronic pain conditions, metabolic dysfunction, and regenerative biomarkers such as stem cell activity. Epidemiological relevance was assessed through its scalability, accessibility, and potential for population-level health impact.Results: Preliminary findings suggest that biophoton platform technology may influence key biological pathways associated with chronic disease progression, including mitochondrial function, redox balance, and cellular signaling. Observational and pilot clinical data indicate improvements in functional outcomes, reduction in symptom severity, and enhancement of regenerative capacity across diverse chronic conditions. From an epidemiological perspective, the non-invasive nature and potential for continuous use position this technology as a scalable intervention that may reduce disease burden, improve quality of life, and lower long-term healthcare costs.Conclusion: Biophoton platform technology represents a novel and promising adjunct within the evolving landscape of public health innovation. By targeting fundamental bioenergetic and regulatory mechanisms, it offers a complementary pathway to address the root contributors of chronic disease epidemiology. Further large-scale, controlled clinical studies are warranted to validate these findings and establish their role in global health strategies.